TURIN, Italy - Solidsoft Reply, part of the Reply Group, has completed a significant migration of Finland's National Medicines Verification System to its proprietary National Blueprint solution, setting a precedent within the European Medicines Verification System (EMVS). The project, which involved transferring over 500 million medicine pack records accumulated over four years, was accomplished through a 10-month collaboration with the Finnish Medicines Verification Organisation (FiMVO).
The National Blueprint Solution, developed by Solidsoft Reply, leverages Microsoft (NASDAQ:MSFT) Azure cloud technology to ensure compliance with the EU Falsified Medicines Directive (FMD). This directive mandates the authentication of medicines to prevent counterfeit products from entering the supply chain. The migration represents the first of its kind within the EMVS, marking a milestone in the healthcare and pharmaceutical sectors where data integrity and security are crucial.
David Eccles, Partner at Solidsoft Reply, highlighted the migration as a testament to their engineering expertise and collaborative approach. The project's success was attributed to the partnership with FiMVO, which facilitated the overcoming of technical challenges and set a new standard for the EMVS ecosystem.
Maija Gohlke, General Manager at FiMVO, praised the professionalism of Solidsoft Reply's team, noting their knowledge, dedication, and flexibility exceeded expectations. The smooth execution of the project, despite its complexity and the numerous connections within the supply chain, was particularly commended.
Solidsoft Reply is recognized as a leading partner in verification and traceability systems worldwide, particularly within the Pharmaceutical & Healthcare industries. The successful migration of Finland's system is indicative of the company's commitment to enhancing healthcare systems through advanced technology, contributing to the safety and efficacy of healthcare delivery.
The news is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.